Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > LATEST
LATEST
-
REGULATORY Centrist Reform Alliance Warns US MFN Policy Poses “Real Crisis” for Drug Access
July 3, 2026
-
BUSINESS Sawai Prevails in ALS Drug Contract Appeal against Neugen
July 3, 2026
-
ORGANIZATION FPMAJ Sets Up Drug Security Task Force under Chairman
July 3, 2026
-
BUSINESS Insilico, Takeda Ink AI Drug Discovery Deal Worth Up to US$600 Million
July 3, 2026
-
BUSINESS Otsuka’s Voyxact Shows Two-Year Kidney Benefit in PIII IgAN Trial
July 3, 2026
-
BUSINESS PeptiDream, NCC Start FIH Study of CLDN18.2 Radiopharmaceutical
July 3, 2026
-
BUSINESS PeptiDream Poaches 3 EVPs to Bolster Global Expansion
July 3, 2026
-
BUSINESS Eisai’s Dayvigo Accepted for UK Regulatory Review
July 3, 2026
-
BUSINESS Kowa Wins Hong Kong Approval for Livalo, Glanatec OK in Vietnam
July 3, 2026
-
BUSINESS Medinet Exercises Option for Stempeucel Rights in Japan
July 3, 2026
-
REGULATORY Ishin Urges Govt to Make Healthcare, Drug Innovation Core Growth Strategy
July 3, 2026
-
BUSINESS Average Pay at 21 Japan Drug Makers Up 3.8%, Chugai Tops 13 Million Yen
July 2, 2026
-
REGULATORY MHLW Seeks Sponsors for 6 High-Need Unapproved, Off-Label Drugs
July 2, 2026
-
REGULATORY MHLW Orders Label Revisions for Four Pediatric Antibiotics
July 2, 2026
-
ORGANIZATION JETRO Opens 2026 Applications for Regenerative Medicine Program
July 2, 2026
-
BUSINESS Mochida Seeks Pediatric Expansion for Urece
July 2, 2026
-
BUSINESS Kowa Files US NDA for Nicox’s Glaucoma Drug
July 2, 2026
-
BUSINESS GNI Closes Acquisition of Ayumi Pharma
July 2, 2026
-
BUSINESS Toho to Acquire Ishin Pharma, Bring Allostem Distribution In-House
July 2, 2026
-
BUSINESS Kyowa Kirin Selected for FDA Pilot to Speed US Plant Launch
July 2, 2026
ページ
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…